Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Lanreotide (Somatuline) vs Sincalide (Kinevac)
An educational, source-based comparison of Lanreotide (Somatuline) and Sincalide (Kinevac) — how each peptide works, what it's researched for, and what to know before going deeper.
Long-acting somatostatin analog for acromegaly and NETs.
Cyclic octapeptide somatostatin analog with high affinity for SSTR2 and SSTR5. Suppresses GH secretion and slows progression of gastroenteropancreatic neuroendocrine tumors.
- Acromegaly
- Gastroenteropancreatic NETs
- Carcinoid syndrome
- • FDA-approved.
- • Monitor gallbladder, glucose, and thyroid function.
Synthetic C-terminal octapeptide of cholecystokinin for gallbladder imaging.
Synthetic CCK-8 that binds CCK-A receptors on gallbladder smooth muscle, triggering contraction; used to assess gallbladder ejection fraction in cholescintigraphy.
- Gallbladder ejection fraction (HIDA scan)
- Pancreatic secretion testing
- Small bowel transit imaging
- • FDA-approved.
- • Abdominal cramping, nausea, diarrhea common; contraindicated in suspected gallstone obstruction.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Lanreotide (Somatuline) | CLARINET trial | NEJM | 2014 | Lanreotide significantly prolonged progression-free survival in enteropancreatic NETs. |
| Sincalide (Kinevac) | Standardized sincalide cholescintigraphy guideline | J Nucl Med | 2010 | Established 60-minute infusion as optimal for reproducible GBEF. |
Side-effect & safety grid
- FDA-approved.
- Monitor gallbladder, glucose, and thyroid function.
- FDA-approved.
- Abdominal cramping, nausea, diarrhea common; contraindicated in suspected gallstone obstruction.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Lanreotide (Somatuline) vs Sincalide (Kinevac) — Key differences
- Class: Lanreotide (Somatuline) is classified as Somatostatin Analog · Oncology, while Sincalide (Kinevac) is CCK Analog · Diagnostics.
- Primary research focus: Lanreotide (Somatuline) — acromegaly; Sincalide (Kinevac) — gallbladder ejection fraction (hida scan).
- Tag: FDA-Approved · Endocrine vs FDA-Approved · Diagnostics.
Lanreotide (Somatuline) — Frequently Asked Questions
What is the difference between lanreotide and octreotide?+
Both lanreotide and octreotide are long-acting somatostatin analogues used in research and FDA-approved treatment of acromegaly and neuroendocrine tumors. Lanreotide (Somatuline Depot) is a deep-subcutaneous injection dosed every 4 weeks; octreotide LAR is an intramuscular injection dosed every 4 weeks. Head-to-head studies show comparable biochemical control of GH and IGF-1 in acromegaly and comparable symptom control in carcinoid syndrome, with differences primarily in injection route, patient- vs clinic-administered options, and pharmacokinetic profile.
How is octreotide to lanreotide conversion done in research?+
Published switching studies typically convert patients from octreotide LAR 10 / 20 / 30 mg every 4 weeks to lanreotide autogel 60 / 90 / 120 mg every 4 weeks respectively as an approximate dose equivalence, at the next scheduled octreotide dose. Clinical monitoring of IGF-1 (acromegaly) or 5-HIAA and symptom frequency (carcinoid) is used to titrate over subsequent cycles. This is not a clinical recommendation — actual switching is guided by an endocrinologist or oncologist.
Is switching from octreotide to lanreotide well tolerated?+
In published switch studies, most patients maintain biochemical and symptom control after transitioning from octreotide LAR to lanreotide autogel. Reported benefits include patient- or partner-administered deep-SC injection at home and reduced injection-site reactions in some cohorts. GI side effects (steatorrhea, cholelithiasis risk) are broadly similar across the class.
Lanreotide vs octreotide half-life — how do they compare?+
Native octreotide has a plasma half-life of ~1.5 hours; octreotide LAR depot releases over ~4 weeks. Lanreotide autogel is a supersaturated aqueous gel providing sustained release with a mean apparent half-life of ~25–30 days after deep-SC injection, supporting monthly dosing.